Commercial Insight: Top 20 Cancer Therapy Brands Forecast

Datamonitor, October 2010

Introduction

The top 20 cancer therapies achieved sales of over $30 billion in 2009 accounting for 75% of all cancer therapy sales.

The commercial success experienced by the key companies in the cancer therapy market makes the market extremely attractive to drug developers.

The entire branded cancer therapies market will grow from $40.6 billion in 2009 to $57.2 billion in 2019 at a CAGR of 3.5%

Reasons to Purchase

- Quantify the performance of each of the top 20 cancer therapy brands in the seven major markets in 2009 and 2019
- Acquire a detailed account of top-selling cancer brand dynamics and the events that drive and limit their market growth
- Acquire a detailed account of the key developers in the cancer therapy market and their forecast performance in the 7MM over the period 2009-2019

Customers who bought this item also bought

• Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake
• Market and Product Forecasts: Top 20 Oncology Therapy Brands 2011-21 - Avastin fails to top any individual market in 2011
• Commercial Insight: Cytotoxic Therapies - Drug launches in rare indications to offset the decline in cytotoxic sales
• Global Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2012
• Personalized Medicine - Scientific and Commercial Aspects
• Global Prostate Cancer Epidemiology and Patient Flow Analysis - 2012
• Global Prostate Cancer Therapeutics Market (2010 – 2020) (Opportunity Analysis, Pipeline Assessment & Market Forecast)
• Prostate Cancer (Event Driven)
• Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players
• Non-Small-Cell Lung Cancer (Event Driven)